AGOMAB

Serial Number 79408296
680

Registration Progress

Application Filed
Sep 18, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Examiner's Amendment Completed
Due: Jul 26, 2025 7 days

Trademark Image

AGOMAB

Basic Information

Serial Number
79408296
Filing Date
September 18, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
680
Status Date
Jul 15, 2025
Application
Pending
Classes
005 042

Rights Holder

AgomAb Therapeutics NV

32
Address
Posthoflei 1 /6
B-2600 Antwerp (Berchem)
BE

Ownership History

AgomAb Therapeutics NV

Original Applicant
32
BE

Legal Representation

Attorney
Thomas A. Polcyn

USPTO Deadlines

Next Deadline
7 days remaining
Examiner's Amendment Completed
Due Date
July 26, 2025

Application History

18 events
Date Code Type Description Documents
Jul 15, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 11, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 11, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 11, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 11, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jul 3, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 3, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 3, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 24, 2025 RFNT P REFUSAL PROCESSED BY IB Loading...
May 5, 2025 RFRR P REFUSAL PROCESSED BY MPU Loading...
May 5, 2025 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Mar 20, 2025 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Mar 19, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 17, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 3, 2025 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Nov 4, 2024 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Nov 4, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 31, 2024 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical and medical preparations for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; chemical preparations for medical and pharmaceutical purposes, namely, for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; pharmaceutical and medical preparations for use in relation to treating fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs, namely, medicinal preparations for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; antibodies; pharmaceutical and medical preparations incorporating antibodies for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair
Class 042
Scientific research and development services; Scientific research in the nature of conducting clinical trials for others; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and product design of pharmaceutical and medical preparations; pharmaceutical drug development and discovery services; laboratory and medical laboratory product research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaid

Classification

International Classes
005 042